---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Storage and supply questions"
description: "Storage and supply questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: How supplied. Questions: How is KEYTRUDA stored, including after dilution? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Storage and supply questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## How supplied

<a id="keytruda-storage"></a>

### How is KEYTRUDA stored, including after dilution?

> “KEYTRUDA injection (clear to slightly opalescent, colorless to slightly yellow solution):
> Carton containing one 100 mg/4 mL (25 mg/mL), single-dose vial (NDC 0006-3026-02)
> Carton containing two 100 mg/4 mL (25 mg/mL), single-dose vials (NDC 0006-3026-04)
> Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do
> not freeze. Do not shake.”

Source: [KEYTRUDA: Prescribing information, page 195, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=195)

> “The product does not contain a preservative.
>
> Store the diluted solution from the KEYTRUDA 100 mg/4 mL vial either:
>
> At room temperature (temperatures at or below 25°C) for no more than 6 hours from the time of dilution. This includes room temperature storage of the diluted solution, and the duration of infusion.
> Under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 96 hours from the time of dilution. If refrigerated, allow the diluted solution to come to room temperature prior to administration. Do not shake.
> Discard the diluted solution after 6 hours at room temperature or after 96 hours under refrigeration.
> Do not freeze.”

Source: [KEYTRUDA: Preparation, Storage and Administration of KEYTRUDA® (pembrolizumab) | HCP, captured 2026-11-08](https://www.keytrudahcp.com/dosing/preparation-storage-administration/#:~:text=The%20product%20does%20not%20contain,Do%20not%20freeze.)

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
